WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the second quarter ended June 30, 2025, and provided regulatory and clinical updates. "We've made tremendous progress in 2025, and July was a pivotal month for ProKidney with the release of positive topline data from our Phase 2 REGEN-007 study and alignment w ...